Literature DB >> 2499251

Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.

G W Kaatz1, S M Seo, S L Barriere, L M Albrecht, M J Rybak.   

Abstract

The efficacy of fleroxacin versus that of vancomycin was assessed by using the rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Animals were treated with fleroxacin (30 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg every 6 h) for 4 days. These antimicrobial agents were equally effective in clearing bacteremia, reducing bacterial counts in vegetations and tissues, and curing endocarditis. However, resistance to fleroxacin at fivefold the MIC arose in the test strain of S. aureus in 8% of animals that received the drug. We conclude that fleroxacin is as efficacious as vancomycin in this model of a serious systemic S. aureus infection, but modest resistance to fleroxacin may develop during therapy.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2499251      PMCID： PMC172471          DOI： 10.1128/AAC.33.4.519

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.

Authors:  N X Chin; D C Brittain; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

3.  Automated fluorescence polarization immunoassay for monitoring vancomycin.

Authors:  K S Schwenzer; C H Wang; J P Anhalt
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

4.  Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

Authors:  C W Stratton; L B Reller
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

5.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

6.  Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits.

Authors:  S L Barriere; G W Kaatz; D R Schaberg; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S L Barriere; D R Schaberg; R Fekety
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

8.  Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  M Gilbert; J A Boscia; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

9.  Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.

Authors:  E Weidekamm; R Portmann; K Suter; C Partos; D Dell; P W Lücker
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

10.  Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S L Barriere; D R Schaberg; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191
View more
  8 in total

1.  Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

2.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

4.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 5.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

6.  Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 7.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

8.  Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.

Authors:  C Chuard; M Herrmann; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.